share_log

UBS Initiates Coverage On Chimera Investment With Neutral Rating, Announces Price Target of $5.5

UBS Initiates Coverage On Chimera Investment With Neutral Rating, Announces Price Target of $5.5

瑞银以中性评级启动对奇美拉投资的报道,宣布目标股价为5.5美元
Benzinga ·  2023/12/06 06:52

UBS analyst Douglas Harter initiates coverage on Chimera Investment (NYSE:CIM) with a Neutral rating and announces Price Target of $5.5.

瑞银分析师道格拉斯·哈特以中性评级开始报道奇美拉投资(纽约证券交易所代码:CIM),并宣布目标股价为5.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发